Look­ing to win over some skep­ti­cal an­a­lysts, Rhythm beats the drum on in­ter­im da­ta in PhII bas­ket study for ad­di­tion­al in­di­ca­tions

Rhythm Phar­ma­ceu­ti­cals has been work­ing to­ward ex­pand­ing the FDA ap­proval they re­ceived just two months ago for three rare ge­net­ic dis­or­ders that re­sult in obe­si­ty …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER